They are now back to almost square one, screening for indications and patient populations. Will not cost much (either time or money) to switch over to the back up now. The moa is the same, so the data already gathered is of value.
Even if they are little or no better than Bavi, it would extend patent protection and partially lose the stigma associated with Bavi+chemo failure.
Market Data 
Markets 
AI
